Floatz logo

5-FLUOROURACIL-1.BETA.-D-RIBOFURANOSIDE

Neoadjuvant Treatment

Shanghai Minimally Invasive Surgery CenterSmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Neoadjuvant Treatment cohort.

Asset / SponsorPhaseRating
Eloxatin
Shanghai Minimally Invasive Surgery Center
Phase 2B
Cetuximab
Shanghai Minimally Invasive Surgery Center
Phase 2CCC
Catequentinib
Shanghai Minimally Invasive Surgery Center
Phase 2CCC
Capecitabine
Shanghai Minimally Invasive Surgery Center
Phase 2CCC
Pembrolizumab
Peking University Cancer Hospital & Institute
Phase 2CCC

View all 9 →

Same molecule, other indications

5-FLUOROURACIL-1.BETA.-D-RIBOFURANOSIDE is also rated in:

cancerDormant
CC
Indicative ·
46 / 100
View asset →
BevacizumabDormant
CC
Indicative ·
45 / 100
View asset →
Rectal CancerDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →